ホーム>>Signaling Pathways>> Chromatin/Epigenetics>> PARP>>CAY10749

CAY10749

カタログ番号GC47055

Cay10749(化合物15)は、PARP-1、PARP-2、PI3K&&###945 ;, PI3K&&&&&&&&&&&&&&&&&&&777年にわたるPI3K/PI3KのPIC50値を持つ強力なPARP/PI3K阻害剤です。 offlineefficient_models_2022q2.md.en_ja_2022q2.mdCAY10749 is a highly effective anticancer compound targeted against a wide range of oncologic diseases.en_ja_2022q2.md

Products are for research use only. Not for human use. We do not sell to patients.

CAY10749 化学構造

Cas No.: 2337386-47-5

サイズ 価格 在庫数 個数
1 mg
$103.00
在庫あり
5 mg
$464.00
在庫あり
10 mg
$742.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

CAY10749 is a dual inhibitor of poly(ADP-ribose) polymerase (PARP) and PI3K (IC50s = 6.03, 3.63, 5.62, and 7.41 nM for PARP1, PARP2, PI3Kα, and PI3Kδ, respectively).1 It is selective for these enzymes over PI3Kβ and PI3Kγ (IC50s = 288.4 and 831.76 nM, respectively), as well as a panel of 374 additional kinases at 1 µM. CAY10749 (1 µM) induces dsDNA break formation in a neutral comet assay and apoptosis in MDA-MB-468 breast cancer cells. It inhibits proliferation of eight cancer cell lines, including pancreatic, ovarian, lymphoma, leukemia, and lung cancer cells, with IC50 values ranging from 398.11 to 2,818.38 nM. CAY10749 (50 mg/kg twice per day) reduces tumor growth by 73.4% in an MDA-MB-468 mouse xenograft model.

1.Wang, J., Li, H., He, G., et al.Discovery of novel dual poly(ADP-ribose)polymerase (PARP) and phosphoinositide 3-kinase (PI3K) inhibitors as a promising strategy for cancer therapyJ. Med. Chem.63(1)122-139(2019)

レビュー

Review for CAY10749

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CAY10749

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.